Skip to main content
Premium Trial:

Request an Annual Quote

iPSC-based Biotech Firm Orig3N Raises $3.1M

NEW YORK (GenomeWeb) – Orig3N, a biotechnology firm developing a disease-modeling platform targeting rare genetically inherited diseases, today announced it raised $3.1 million in a private round of financing. 

The proceeds will go toward expanding Boston-based Orig3N's Life Capsule, a bio-repository for people to contribute their cells via a blood sample. The cells are reprogrammed into induced pluripotent stem cells, which can be used for disease modeling outside the body for medical research, as well as for individualized therapy. 

Participants in the financing included Hatteras Venture Partners, Harris & Harris Group, KTB, and Mountain Group Capital.